At-home dog tests are also a race to own your dog's data.

A little over two years ago, Oncotect launched what it billed as the first at-home cancer screen for dogs, a mail-in urine test, for $249.99. Today that test runs about $90 and is still drifting down. It proved that an owner would mail in a sample and pay to know, and the price has dropped by roughly two thirds since.

A few of the companies that followed are doing something genuinely different. They are reading a dog's blood, its gut, and even its fur, and reaching past cancer toward organ decline, joint disease, and gut health. Some are built on proprietary methods and PhD science with clinical studies underway. Others have taken a lab panel that has existed for years and wrapped it in a clean app. Same shelf, very different things underneath.

The pitch is the same across all of them. Testing that used to mean a vet drawing blood, then days of waiting for a phone call and an emailed report you can barely read, now means a kit on the porch and a result in an app that feels closer to an Oura ring than a lab printout. It is cheaper, it is easier to make sense of, and it spares an owner an extra visit and an extra panel fee. The appeal is real.

The trouble is that these are not one product doing one job. They run on different science, they measure different things, and they do not even agree on what your dog's normal is. Two questions are worth holding onto as you look. Is the biomarker actually measuring something real, and is the test comparing your dog to a breed-average chart or learning what is normal for your specific pup?

What follows is a closer look at the field, the very different businesses sharing one shelf, the size of the opportunity they are chasing, and what is worth watching as the category takes shape.